SEARCH

SEARCH BY CITATION

References

  • 1
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:14851492. MEDLINE
  • 2
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:14261432. MEDLINE
  • 3
    Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339:14931499. MEDLINE
  • 4
    Poynard T, McHutchison J, Goodman Z, Ling M-H, Albrecht J. Is an “A la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first liner treatment in patients with chronic hepatitis C? HEPATOLOGY 2000;31;211218. MEDLINE
  • 5
    Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:372374. MEDLINE
  • 6
    Pockros PJ, Bain VG, Hunter EB, Conrad A, Balart A, Hollinger FB, Albert D. A comparison of reverse transcription-polymerase chain reaction and branched-chain DNA assays for hepatitis C virus RNA in patients receiving interferon treatment. J Viral Hepat 1999; 6:145150. MEDLINE
  • 7
    Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Heuverswyn HV, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74:10931102. MEDLINE
  • 8
    Consensus statement. EASL International Consensus Conference on hepatitis C. J Hepatol 1999; 30:956961. MEDLINE
  • 9
    Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. HEPATOLOGY 1996; 24:778789. MEDLINE
  • 10
    Alberti A, Chemello L, Noventa F, Cavaletto L, De Salvo G. Therapy of hepatitis C: re-treatment with alpha interferon. HEPATOLOGY 1997; 26(Suppl):137S142S. MEDLINE
  • 11
    Heathcote EJL, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Albert DG, et al. Re-treatment of chronic hepatitis C with consensus interferon. HEPATOLOGY 1998; 27:11361143. MEDLINE
  • 12
    Cavaletto L, Chemello L, Donado C, Casarin P, Belussi F, Bernardinello E, Marino F, et al. The pattern of response to interferon alpha (α-IFN) predicts sustained response to a 6-month α-IFN and ribavirin retreatment for chronic hepatitis C. J Hepatol 2000; 33:128134. MEDLINE
  • 13
    Pol S, Couzigou P, Bourliere M, Abergel A, Combis J-M, Larrey D, Tran A, et al. A randomized trial of ribavirin and interferon-α vs interferon-α alone in patients with chronic hepatitis C who were non-responders to a previous treatment. J Hepatol 1999; 31:17. MEDLINE
  • 14
    Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Bellomo G, Belloni G, Grisorio B, et al. Interferon-α-2b and ribavirin in combination for chronic hepatitis C patients not responding to interferon-a alone: an Italian multicenter, randomized, controlled, clinical study. Am J Gastroenterol 1998; 93:24452451. MEDLINE
  • 15
    Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. HEPATOLOGY 1999; 30:787793. MEDLINE
  • 16
    Bonis PA, Ioannidis JP, Cappelleri JC, Kaplan MM, Lau J. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics. HEPATOLOGY 1997; 26:10351044. MEDLINE
  • 17
    Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, Killenberg P, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multi-center, prospective, randomized, controlled trial. HEPATOLOGY 2000; 32:135138. MEDLINE
  • 18
    Boucher E, Jouanolle H, Andre P, Ruffault A, Guyader D, Moirand R, Turlin B, et al. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients. HEPATOLOGY 1995; 21:322327. MEDLINE
  • 19
    Shiffmann ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK, Ferreira-Gonzalez A, et al. A randomised, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999; 117:11641172. MEDLINE
  • 20
    Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. HEPATOLOGY 1997; 26(Suppl):133S136S. MEDLINE